ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -31 مورد

Tenofovir alafenamide: Drug information

Tenofovir alafenamide: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Tenofovir alafenamide: Patient drug information" and "Tenofovir alafenamide: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Post-treatment severe acute exacerbation of hepatitis B:

Discontinuation of anti-hepatitis B therapy, including tenofovir alafenamide, may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including tenofovir alafenamide. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Brand Names: US
  • Vemlidy
Brand Names: Canada
  • Vemlidy
Pharmacologic Category
  • Antihepadnaviral, Reverse Transcriptase Inhibitor, Nucleotide (Anti-HBV)
Dosing: Adult
Hepatitis B virus infection, treatment

Hepatitis B virus infection, treatment: Oral: 25 mg once daily.

Treatment duration: Treatment duration is variable and influenced by hepatitis B e antigen (HBeAg) status, duration of hepatitis B virus (HBV) suppression, and presence of cirrhosis/decompensation (Ref).

Patients without cirrhosis:

HBeAg-positive immune-active chronic hepatitis: Treat until HBeAg seroconversion; after seroconversion, prolonged duration of therapy is often required in patients treated with nucleos(t)ide analogues. Optimal duration is unknown; however, consolidation therapy is generally a minimum of 12 months of persistently normal ALT and undetectable serum HBV DNA levels after HBeAg seroconversion (Ref).

HBeAg-negative immune-active chronic hepatitis: Indefinite antiviral therapy is suggested unless there is compelling rationale for discontinuation (risk/benefit decision); treatment discontinuation may be considered in patients with loss of HBsAg; however, there is insufficient evidence to guide decisions in these patients (Ref).

Patients with cirrhosis:

HBeAg-positive immune-active chronic hepatitis: In patients who seroconvert on therapy, continue antiviral therapy indefinitely due to concerns with decompensation and death, unless there is a strong competing rationale for discontinuation (Ref).

HBeAg-negative immune-active chronic hepatitis: Treatment discontinuation is not recommended due to potential for decompensation and death (limited data) (Ref).

Viral breakthrough : Patients with confirmed viral breakthrough (HBV DNA ≥100 IU/mL with previously undetectable levels [<10 IU/mL] or >1 log increase in HBV DNA compared to nadir), should either be switched to an alternative antiviral monotherapy agent with a high genetic barrier to resistance or receive a second antiviral agent with a complementary resistance profile; consult current clinical practice guidelines for recommended agents (Ref).

Hepatitis B virus reactivation prophylaxis, immunocompromised patients

Hepatitis B virus reactivation prophylaxis , immunocompromised patients (off-label use): Oral: 25 mg once daily (Ref).

Hepatitis B virus reinfection prophylaxis, post liver transplant

Hepatitis B virus reinfection prophylaxis , post liver transplant (with or without hepatitis B immune globulin) (off-label use): Oral: 25 mg once daily (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: Tenofovir is renally cleared, and exposures are increased in patients with CrCl <30 mL/minute and those receiving hemodialysis (Ref). Close monitoring for adverse effects in the advanced stages of kidney dysfunction is recommended. Kidney function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.

Kidney impairment prior to treatment initiation:

Altered kidney function: Oral:

CrCl ≥30 mL/minute: No dosage adjustment necessary (Ref).

CrCl 15 to <30 mL/minute: No dosage adjustment necessary (Ref); however, population pharmacokinetic modeling predicts increased tenofovir plasma AUC0-24 in patients with CrCl 15 to 29 mL/minute receiving once daily dosing compared to those with normal kidney function (1,000 ng*hour/mL versus to 298 ng*hour/mL, respectively) and that administering 25 mg every 48 hours would reduce the risk of toxicity while still achieving adequate intracellular tenofovir concentrations (Ref).

CrCl <15 mL/minute: Use is not recommended (Ref). Alternatively, population pharmacokinetic modeling predicts increased tenofovir plasma AUC0-24 in patients with CrCl <15 mL/minute receiving once daily dosing compared to those with normal kidney function (1,610 ng*hour/mL versus to 298 ng*hour/mL, respectively) and that administering 25 mg every 72 hours would reduce the risk of toxicity while still ensuring sufficient intracellular tenofovir concentrations (Ref).

Hemodialysis, intermittent (thrice weekly): No dosage adjustment necessary; when scheduled dose falls on a dialysis day, administer after dialysis.

Peritoneal dialysis: Limited data available. One case report found that plasma tenofovir and intracellular tenofovir diphosphate trough concentrations were 15-fold and 2-fold higher in a patient on peritoneal dialysis compared to people with normal kidney function. Consider alternative therapies in peritoneal dialysis patients to minimize toxicity and preserve residual kidney function (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary. When scheduled dose falls on PIRRT days, administer after PIRRT (Ref).

Nephrotoxicity during treatment: Discontinue use in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.

Dosing: Liver Impairment: Adult

Mild impairment (Child-Pugh class A): No dosage adjustment necessary.

Decompensated cirrhosis (Child-Pugh class B or C): Use is not recommended.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Tenofovir alafenamide: Pediatric drug information")

Chronic hepatitis B

Chronic hepatitis B (with compensated liver disease):

Children ≥6 years and Adolescents, weighing ≥25 kg: Oral: 25 mg once daily (Ref). Oral antiviral therapy was continued for 1 to 4 years in trials; hepatitis B e antigen (HBeAg) seroconversion has been suggested as a therapeutic end point followed by an additional 12 months of consolidation (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Kidney impairment prior to treatment initiation:

Children ≥6 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Based on experience in adult patients, no dosage adjustment is likely necessary for patients with CrCl ≥15 mL/minute or in those with end-stage renal disease (CrCl <15 mL/minute) receiving chronic hemodialysis (administer after hemodialysis on dialysis days); tenofovir alafenamide is not recommended in adults with CrCl <15 mL/minute who are not receiving chronic hemodialysis. Monitor closely for adverse effects in patients with renal dysfunction.

Nephrotoxicity during treatment:

Children ≥6 years and Adolescents: Discontinue use in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.

Dosing: Liver Impairment: Pediatric

Children ≥6 years and Adolescents:

Mild impairment: No dosage adjustment necessary.

Decompensated impairment: Not recommended.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults, unless otherwise indicated.

>10%:

Nervous system: Headache (12%)

Neuromuscular & skeletal: Decreased bone mineral density (children and adolescents: ≥4% at lumbar spine: 6%; ≥4% whole body: 2%; adults: ≥5% at lumbar spine: 11%; ≥7% at femoral neck: 5%)

1% to 10%:

Cardiovascular: Increased serum creatine kinase (grades 3/4: 3%)

Dermatologic: Skin rash (<5%)

Endocrine & metabolic: Increased LDL cholesterol (grades 3/4: 6%)

Gastrointestinal: Abdominal pain (9%), diarrhea (5%), dyspepsia (5%), flatulence (<5%), increased amylase (grades 3/4: 3%), nausea (6%), vomiting (<5%)

Genitourinary: Glycosuria (grades 3/4: 5%)

Hepatic: Increased serum alanine aminotransferase (grades 3/4: 8%), increased serum aspartate aminotransferase (grades 3/4: 3%)

Nervous system: Fatigue (6%)

Neuromuscular & skeletal: Arthralgia (5%), back pain (6%)

Respiratory: Cough (8%)

Frequency not defined:

Endocrine & metabolic: Decreased HDL cholesterol, increased serum triglycerides

Gastrointestinal: Increased serum lipase

Hepatic: Exacerbation of hepatitis B

Postmarketing:

Dermatologic: Urticaria

Hypersensitivity: Angioedema

Renal: Acute kidney injury, Fanconi syndrome, proximal tubular nephropathy, renal tubular necrosis

Contraindications

There are no contraindications listed in the US manufacturer's labeling.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to tenofovir alafenamide or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, sometimes fatal, have been reported with the use of nucleoside analogs, alone or in combination with other antiretrovirals. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity. Marked transaminase elevation may/may not accompany hepatomegaly and steatosis.

• Kidney toxicity: Kidney toxicity (acute renal failure, Fanconi syndrome, and/or proximal renal tubulopathy) has been reported with use of tenofovir alafenamide–containing products; patients with impaired renal function and those with concurrent or recent nephrotoxic therapy (including nonsteroidal anti-inflammatory drug use) are at an increased risk.

Disease-related concerns:

• Liver impairment: Dosage adjustment may be required.

• HIV-1 and HBV coinfection: Should not be used as a single agent for the treatment of HIV-1 due to resistance development risk.

Other warnings/precautions:

• HIV testing: HIV antibody testing should be offered to all HBV infected patients prior to treatment initiation. If HIV testing is positive, institute an appropriate antiretroviral (HIV-1) combination regimen.

Warnings: Additional Pediatric Considerations

Through disruption in vitamin D metabolism, decreases in bone mineral density (BMD) have been observed with tenofovir alafenamide (TAF) after 48 weeks of treatment; however, the incidence and negative impact on BMD is less than that observed with tenofovir disoproxil fumarate (TDF). Additionally, TAF is associated with less renal toxicity than TDF but equal antiviral efficacy. A higher incidence of dyslipidemia has been reported with TAF than TDF. Do not use TAF and TDF concomitantly (HHS [pediatric] 2022).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Vemlidy: 25 mg

Generic Equivalent Available: US

No

Pricing: US

Tablets (Vemlidy Oral)

25 mg (per each): $61.07

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Vemlidy: 25 mg

Administration: Adult

Oral: Administer with food.

Administration: Pediatric

Oral: Administer with food.

Use: Labeled Indications

Hepatitis B virus infection, treatment: Treatment of hepatitis B virus infection in adults and pediatric patients ≥6 years of age and weighing ≥25 kg with compensated liver disease.

Note: Although tenofovir alafenamide as a single agent is not FDA-approved for HIV-1 infection, it is approved for treatment and/or preexposure prophylaxis of HIV-1 infection as part of several fixed-dose combination products; refer to those product monographs for more information.

Use: Off-Label: Adult

Hepatitis B virus reactivation prophylaxis, immunocompromised patients; Hepatitis B virus reinfection prophylaxis, post liver transplant

Medication Safety Issues
Other safety concerns:

TAF is an error-prone abbreviation (mistaken as tenofovir disoproxil fumarate)

Metabolism/Transport Effects

Substrate of BCRP, OAT1/3, OATP1B1/1B3, P-glycoprotein (Major with inducers), P-glycoprotein (Minor with inhibitors); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits MRP2;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Acyclovir-Valacyclovir: May increase serum concentration of Tenofovir Products. Tenofovir Products may increase serum concentration of Acyclovir-Valacyclovir. Risk C: Monitor

Adefovir: May decrease therapeutic effects of Tenofovir Products. Adefovir may increase serum concentration of Tenofovir Products. Tenofovir Products may increase serum concentration of Adefovir. Risk X: Avoid

Aminoglycosides: May increase serum concentration of Tenofovir Products. Tenofovir Products may increase serum concentration of Aminoglycosides. Risk C: Monitor

Atidarsagene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Atidarsagene Autotemcel. Risk X: Avoid

Betibeglogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Betibeglogene Autotemcel. Risk X: Avoid

Cabozantinib: MRP2 Inhibitors may increase serum concentration of Cabozantinib. Risk C: Monitor

CarBAMazepine: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Cidofovir: May increase serum concentration of Tenofovir Products. Tenofovir Products may increase serum concentration of Cidofovir. Risk C: Monitor

Cladribine: Agents that Undergo Intracellular Phosphorylation may decrease therapeutic effects of Cladribine. Risk X: Avoid

Cobicistat: May increase serum concentration of Tenofovir Alafenamide. Risk C: Monitor

Elivaldogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Elivaldogene Autotemcel. Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished Risk X: Avoid

Fosphenytoin-Phenytoin: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Ganciclovir-Valganciclovir: Tenofovir Products may increase serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase serum concentration of Tenofovir Products. Risk C: Monitor

Lovotibeglogene Autotemcel: Antiretroviral Agents may decrease therapeutic effects of Lovotibeglogene Autotemcel. Risk X: Avoid

Lumacaftor and Ivacaftor: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may decrease serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Risk C: Monitor

Nirmatrelvir and Ritonavir: May increase serum concentration of Tenofovir Alafenamide. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents (Topical): May increase nephrotoxic effects of Tenofovir Products. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents: May increase nephrotoxic effects of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk. Risk D: Consider Therapy Modification

Orlistat: May decrease serum concentration of Antiretroviral Agents. Risk C: Monitor

OXcarbazepine: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

P-glycoprotein/ABCB1 Inducers: May decrease serum concentration of Tenofovir Alafenamide. Management: Consider alternatives to the use of P-gp inducers with tenofovir alafenamide. If combined, monitor for reduced tenofovir alafenamide concentrations and efficacy, and for the development of resistance. Risk D: Consider Therapy Modification

PHENobarbital: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Primidone: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Rifabutin: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

RifAMPin: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Rifapentine: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Ritonavir: May increase serum concentration of Tenofovir Alafenamide. Risk C: Monitor

St John's Wort: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Tacrolimus (Systemic): Tenofovir Products may increase nephrotoxic effects of Tacrolimus (Systemic). Risk C: Monitor

Tipranavir: May decrease serum concentration of Tenofovir Alafenamide. Risk X: Avoid

Reproductive Considerations

Contraception is not required to initiate or continue antiretroviral therapy.

Tenofovir alafenamide is a preferred nucleoside reverse transcriptase inhibitor in patients with HIV who are not yet pregnant but are trying to conceive.

Tenofovir alafenamide is not effective for preexposure prophylaxis in persons with vaginal exposure to HIV.

Maximum viral suppression sustained below the limits of detection prior to conception is recommended for all persons with HIV who are planning a pregnancy. Prior to pregnancy, select or make changes to a specific antiretroviral regimen as part of a shared decision-making process. In most cases, recommendations based on data obtained from cisgender women can be applied to transgender and gender diverse people assigned female sex at birth.

Health care providers caring for couples planning a pregnancy when one or both partners are diagnosed with HIV may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2024).

Algorithms are available for assessing antiviral prophylaxis and treatment of hepatitis B infection in persons not coinfected with HIV who could become pregnant (WHO 2024).

Pregnancy Considerations

Tenofovir alafenamide has a low level of transfer across the human placenta.

No increased risk of overall teratogenic effects has been observed based on data collected by the antiretroviral pregnancy.

Maternal antiretroviral therapy (ART) may be associated with adverse pregnancy outcomes including preterm birth, low birth weight, and small for GA infants. High viral loads are also associated with adverse outcomes, including preterm birth and pregnancy loss. Treatment improves the health of the pregnant patient and reduces the risk of perinatal transmission. Do not withhold appropriate maternal ART due to concerns for adverse neonatal outcomes. Closely monitor for pregnancy complications. Document in utero ART exposure in the long-term medical record of a child born without HIV; evaluate for potential metabolic dysfunction if significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) develop.

Tenofovir alafenamide is a preferred nucleoside reverse transcriptase inhibitor (NRTI) for pregnant patients with HIV who are antiretroviral naive, who have had ART therapy in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). Patients who become pregnant while taking tenofovir alafenamide may continue if viral suppression is effective and the regimen is well tolerated.

Tenofovir alafenamide with emtricitabine or lamivudine is a preferred NRTI backbone for initial therapy in antiretroviral-naive patients who are pregnant. Tenofovir alafenamide is also a preferred component of a regimen when early (acute/recent) HIV infection is detected during pregnancy; genotyping may be required if the person had prior use of long acting cabotegravir for preexposure prophylaxis.

Tenofovir alafenamide plus emtricitabine or lamivudine is a recommended dual NRTI backbone in regimens for pregnant patients who are HIV/hepatitis B virus–coinfected.

The pharmacokinetics of tenofovir alafenamide are not significantly altered during pregnancy and dose adjustment is not required.

ART is recommended for all pregnant people with HIV to maximize their health, maintain the viral load below the limit of an ultrasensitive assay detection, and reduce the risk of perinatal transmission. Start ART prior to conception or as soon as possible during pregnancy. During pregnancy, select or make changes to a specific antiretroviral regimen as part of a shared decision-making process. Patients on fully suppressive regimens prior to pregnancy generally may continue the same regimen considering known pregnancy outcomes and pharmacokinetic data. Monitor pregnant patients more frequently than nonpregnant patients. ART initiated during pregnancy can be modified after delivery. In most cases, recommendations based on data obtained from cisgender women can be applied to transgender and gender diverse people assigned female sex at birth (HHS [perinatal] 2024).

Algorithms are available for assessing antiviral prophylaxis and treatment of hepatitis B infection in pregnant persons not coinfected with HIV. Tenofovir alafenamide may be considered for use during pregnancy (WHO 2024). Patients using tenofovir alafenamide prior to conception should continue use during pregnancy (SMFM [Badell 2024]).

Data collection to monitor pregnancy and infant outcomes following exposure to ART is ongoing. Enroll all patients exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263).

Health care providers caring for pregnant patients with HIV and their infants may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2024).

Breastfeeding Considerations

Tenofovir and tenofovir alafenamide are present in breast milk following administration of tenofovir alafenamide (HHS [perinatal] 2024; Kayes 2022; Li 2021; Yang 2021). Tenofovir can be detected in the urine of breastfed infants (HHS [perinatal] 2024).

Tenofovir alafenamide is a recommended component of an initial regimen for early (acute/recent) HIV infection in postpartum patients. Interrupt breastfeeding immediately if seroconversion is suspected and do not continue if infection is diagnosed. Breast milk may be expressed and stored while waiting for test results.

Provide patient-centered evidence-based counseling for infant feeding options as early as possible in pregnancy.

• Using properly prepared formula or pasteurized banked donor milk eliminates the risk of postnatal HIV transmission via breastfeeding.

• Counsel patients on antiretroviral therapy (ART) who achieve and maintain a consistently undetectable plasma viral load during pregnancy and postnatally about feeding options, including breastfeeding, formula feeding, or banked donor milk. Maintaining maximum viral suppression decreases but does not eliminate the risk of HIV transmission via breast milk. Temporary discontinuation of breastfeeding and use of replacement feeding may be required if maternal viral load becomes detectable or if mastitis or bleeding nipples develop. Permanent discontinuation of breastfeeding is recommended if the maternal HIV RNA is ≥200 copies/mL.

• Formula feeding or banked donor milk is recommended for persons with HIV who are not on ART and/or do not have sustained viral suppression. Provide the infant presumptive ART throughout breastfeeding and for up to 6 weeks after the last exposure to breastmilk if the breastfeeding parent does not have sustained viral suppression but breastfeeding is continued; conduct infant virologic diagnostic testing at specified intervals.

• When the HIV status at delivery is not known, breast milk may be expressed and stored until a negative test is available.

• Discontinue breastfeeding immediately if HIV infection is diagnosed after breastfeeding has been initiated.

• Evaluate and provide support for maternal conditions that would make adherence to postpartum ART difficult.

Information is available for counseling and managing patients with HIV who are considering breastfeeding (1-888-448-8765). In most cases, recommendations based on data obtained from cisgender women can be applied to transgender and gender diverse people assigned female sex at birth (HHS [perinatal] 2024).

Patients requiring antivirals for hepatitis B infection (who are not HIV coinfected) may breastfeed if the infant received immunoprophylaxis at birth. If nipples are cracked or bleeding, breastfeeding from the affected breast is not recommended (milk should be expressed and discarded until healed) (SMFM [Badell 2024]).

Monitoring Parameters

General monitoring: Serum creatinine, estimated CrCl, serum phosphorus (in patients with chronic kidney disease), urine glucose, urine protein (prior to initiation and as clinically indicated during therapy); HIV testing (prior to initiation); hepatic function tests; monitor clinical and laboratory data closely for several months following therapy discontinuation.

Hepatitis B virus infection:

Before initiating therapy: Baseline assessment of liver fibrosis or cirrhosis status (eg, aspartate aminotransferase-to-platelet ratio index [APRI] score); bone mineral density, CBC, kidney function, INR, alpha-fetoprotein (AFP), gamma-glutamyl transferase, liver biochemistries, hepatitis B DNA levels and genotype, hepatitis B surface antigen, hepatitis B e antigen. Also screen for HIV, anti-hepatitis A antibodies, anti-hepatitis D antibodies (if considered at risk, such as endemic in country of origin), and hepatitis C RNA to determine need for cotreatment and/or vaccination (AASLD [Terrault 2018]; WHO 2024).

During therapy:

Every visit: Treatment adherence (WHO 2024). Obtain lactic acid level if signs or symptoms of lactic acidosis are present; obtain urine protein and urine glucose if clinically indicated (AASLD [Terrault 2018]).

Every 3 to 6 months for the first year then at least annually thereafter: Liver biochemistries, kidney function, hepatitis B DNA levels, hepatitis B surface antigen, hepatitis B e, tuberculosis (WHO 2024).

Every 6 to 12 months: Liver fibrosis, cirrhosis status; if cirrhosis or risk factors for hepatocellular carcinoma (eg, family history) are present, monitor AFP and abdominal ultrasound every 6 months to enable detection of hepatocellular carcinoma (AASLD [Terrault 2018]; WHO 2024).

Periodically monitor for treatment failure, which is defined as failure of antiviral regimen to reduce HBV viral load by >1 log10 IU/mL within 3 months, or rebound of HBV viral load of >1 log10 IU/mL from nadir at any time during therapy (AASLD [Terrault 2018]; WHO 2024).

If therapy discontinued:

For patients without cirrhosis: Monitor liver biochemistries and hepatitis B serologies every 3 months for 1 year (AASLD [Terrault 2016]; WHO 2024).

For patients with cirrhosis: Monitor liver biochemistries and hepatitis B serologies monthly for 6 months then every 3 months indefinitely to detect recurrence of hepatitis B. Monitor AFP and abdominal ultrasound every 6 months to enable detection of hepatocellular carcinoma (AASLD [Terrault 2016]; WHO 2024).

Mechanism of Action

Tenofovir alafenamide, an analog of adenosine 5'-monophosphate, is converted intracellularly by hydrolysis to tenofovir and subsequently phosphorylated to the active tenofovir diphosphate. The active moiety inhibits replication of HBV by inhibiting HBV polymerase.

Pharmacokinetics (Adult Data Unless Noted)

Protein binding: 80% to plasma proteins.

Metabolism: Tenofovir alafenamide (TAF) is converted intracellularly to tenofovir, then phosphorylated to the active tenofovir diphosphate.

Bioavailability: Increases ~65% with a high-fat meal.

Half-life elimination: 0.51 hours.

Time to peak, serum:

Children ≥4 years and Adolescents ≤15 years: Tenofovir alafenamide: Mean range: 1.1 to 2 hours; Tenofovir: Mean range: 2 to 3 hours (Waalewijn 2023).

Adults: Tenofovir alafenamide: 0.48 hours.

Excretion: Feces (31.7%) and urine (<1%).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: In patients with CrCl 15 to 29 mL/minute or with end-stage renal disease requiring dialysis, Cmax and AUC of tenofovir were increased.

  1. Agarwal K, Fung SK, Nguyen TT, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62(3):533-540. [PubMed 25450717]
  2. Badell ML, Prabhu M, Dionne J, Tita ATN, Silverman NS; Society for Maternal-Fetal Medicine (SMFM). Society for Maternal-Fetal Medicine consult series #69: hepatitis B in pregnancy: updated guidelines. Am J Obstet Gynecol. 2024;230(4):B2-B11. doi:10.1016/j.ajog.2023.12.023 [PubMed 38141870]
  3. Custodio JM, Fordyce M, Garner W, et al. Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob Agents Chemother. 2016;60(9):5135-5140. doi:10.1128/AAC.00005-16 [PubMed 27216057]
  4. Eron JJ Jr, Lelievre JD, Kalayjian R, et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Lancet HIV. 2018:S2352-S3018(18)30296-0. doi:10.1016/S2352-3018(18)30296-0 [PubMed 30555051]
  5. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  6. Inada K, Kaneko S, Kurosaki M, et al. Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. JGH Open. 2021;5(9):1085-1091. doi:10.1002/jgh3.12636 [PubMed 34584979]
  7. Kayes T, Crane H, Symonds A, et al. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. Aliment Pharmacol Ther. 2022;56(3):510-518. doi:10.1111/apt.17040 [PubMed 35599363]
  8. Li B, Liu Z, Liu X, et al. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load. Hepatol Int. 2021;15(5):1103-1108. doi:10.1007/s12072-021-10235-1 [PubMed 34312798]
  9. Massih SA, Atta MG, Thio CL, et al. Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis. AIDS Res Ther. 2024;21(1):34. doi:10.1186/s12981-024-00616-5 [PubMed 38773606]
  10. Rashidi-Alavijeh J, Straub K, Achterfeld A, Wedemeyer H, Willuweit K, Herzer K. Safety and efficacy of tenofovir alafenamide in liver transplant recipients: a single center experience. Transpl Infect Dis. 2021;23(3):e13522. doi:10.1111/tid.13522 [PubMed 33217163]
  11. Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res. 2016;125:63-70. [PubMed 26640223]
  12. Refer to manufacturer's labeling.
  13. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800 [PubMed 29405329]
  14. Thoueille P, Alves Saldanha S, Desfontaine V, et al; Swiss HIV Cohort Study. Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. J Antimicrob Chemother. 2023;78(6):1433-1443. doi:10.1093/jac/dkad103 [PubMed 37042359]
  15. US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines. Updated October 11, 2022. Accessed November 9, 2022.
  16. US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new. Updated December 19, 2024. Accessed December 30, 2024.
  17. Vemlidy (tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2024.
  18. Vemlidy (tenofovir alafenamide) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada, Inc; August 2020.
  19. Waalewijn H, Szubert AJ, Wasmann RE, et al. First pharmacokinetic data of tenofovir alafenamide fumarate and tenofovir with dolutegravir or boosted protease inhibitors in African children: a substudy of the CHAPAS-4 trial. Clin Infect Dis. 2023;77(6):875-882. doi:10.1093/cid/ciad267 [PubMed 37315296]
  20. World Health Organization (WHO). Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. https://www.who.int/publications/i/item/9789240090903. Published 2024.
  21. Yang N, Zhou G, Cheng X, et al. Distribution evaluation of tenofovir in the breast milk of mothers with HBeAg-positive chronic HBV infection after treatment with tenofovir alafenamide and tenofovir disoproxil fumarate by a sensitive UPLC-MS/MS method. Front Pharmacol. 2021;12:734760. doi:10.3389/fphar.2021.734760 [PubMed 34483946]
Topic 110861 Version 125.0